Global Adalimumab Monoclonal Antibody Biosimilar Market Research Report 2024(Status and Outlook)

Global Adalimumab Monoclonal Antibody Biosimilar Market Research Report 2024(Status and Outlook)



Report Overview:

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

The Global Adalimumab Monoclonal Antibody Biosimilar Market Size was estimated at USD 473.99 million in 2023 and is projected to reach USD 960.91 million by 2029, exhibiting a CAGR of 12.50% during the forecast period.

This report provides a deep insight into the global Adalimumab Monoclonal Antibody Biosimilar market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Adalimumab Monoclonal Antibody Biosimilar Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Adalimumab Monoclonal Antibody Biosimilar market in any manner.

Global Adalimumab Monoclonal Antibody Biosimilar Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Cadila Healthcare

Torrent Pharmaceuticals

Amgen

Boehringer Ingelheim

Novartis

Samsung Bioepis

Viatris

Pfizer

Fresenius Kabi

Coherus

Market Segmentation (by Type)

Syringe

Pen

Market Segmentation (by Application)

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Other

Geographic Segmentation
  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Adalimumab Monoclonal Antibody Biosimilar Market
  • Overview of the regional outlook of the Adalimumab Monoclonal Antibody Biosimilar Market:
Key Reasons to Buy this Report:
  • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
  • This enables you to anticipate market changes to remain ahead of your competitors
  • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
  • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6-month post-sales analyst support
Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adalimumab Monoclonal Antibody Biosimilar Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Adalimumab Monoclonal Antibody Biosimilar
1.2 Key Market Segments
1.2.1 Adalimumab Monoclonal Antibody Biosimilar Segment by Type
1.2.2 Adalimumab Monoclonal Antibody Biosimilar Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Adalimumab Monoclonal Antibody Biosimilar Market Overview
2.1 Global Market Overview
2.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Adalimumab Monoclonal Antibody Biosimilar Market Competitive Landscape
3.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Manufacturers (2019-2024)
3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue Market Share by Manufacturers (2019-2024)
3.3 Adalimumab Monoclonal Antibody Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Adalimumab Monoclonal Antibody Biosimilar Sales Sites, Area Served, Product Type
3.6 Adalimumab Monoclonal Antibody Biosimilar Market Competitive Situation and Trends
3.6.1 Adalimumab Monoclonal Antibody Biosimilar Market Concentration Rate
3.6.2 Global 5 and 10 Largest Adalimumab Monoclonal Antibody Biosimilar Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Adalimumab Monoclonal Antibody Biosimilar Industry Chain Analysis
4.1 Adalimumab Monoclonal Antibody Biosimilar Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Adalimumab Monoclonal Antibody Biosimilar Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Adalimumab Monoclonal Antibody Biosimilar Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Type (2019-2024)
6.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Market Share by Type (2019-2024)
6.4 Global Adalimumab Monoclonal Antibody Biosimilar Price by Type (2019-2024)
7 Adalimumab Monoclonal Antibody Biosimilar Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adalimumab Monoclonal Antibody Biosimilar Market Sales by Application (2019-2024)
7.3 Global Adalimumab Monoclonal Antibody Biosimilar Market Size (M USD) by Application (2019-2024)
7.4 Global Adalimumab Monoclonal Antibody Biosimilar Sales Growth Rate by Application (2019-2024)
8 Adalimumab Monoclonal Antibody Biosimilar Market Segmentation by Region
8.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region
8.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales by Region
8.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Market Share by Region
8.2 North America
8.2.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Cadila Healthcare
9.1.1 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.1.2 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.1.4 Cadila Healthcare Business Overview
9.1.5 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar SWOT Analysis
9.1.6 Cadila Healthcare Recent Developments
9.2 Torrent Pharmaceuticals
9.2.1 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.2.2 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.2.4 Torrent Pharmaceuticals Business Overview
9.2.5 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar SWOT Analysis
9.2.6 Torrent Pharmaceuticals Recent Developments
9.3 Amgen
9.3.1 Amgen Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.3.2 Amgen Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar SWOT Analysis
9.3.5 Amgen Business Overview
9.3.6 Amgen Recent Developments
9.4 Boehringer Ingelheim
9.4.1 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.4.2 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.4.4 Boehringer Ingelheim Business Overview
9.4.5 Boehringer Ingelheim Recent Developments
9.5 Novartis
9.5.1 Novartis Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.5.2 Novartis Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.5.4 Novartis Business Overview
9.5.5 Novartis Recent Developments
9.6 Samsung Bioepis
9.6.1 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.6.2 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.6.4 Samsung Bioepis Business Overview
9.6.5 Samsung Bioepis Recent Developments
9.7 Viatris
9.7.1 Viatris Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.7.2 Viatris Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.7.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.7.4 Viatris Business Overview
9.7.5 Viatris Recent Developments
9.8 Pfizer
9.8.1 Pfizer Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.8.2 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.8.4 Pfizer Business Overview
9.8.5 Pfizer Recent Developments
9.9 Fresenius Kabi
9.9.1 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.9.2 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.9.4 Fresenius Kabi Business Overview
9.9.5 Fresenius Kabi Recent Developments
9.10 Coherus
9.10.1 Coherus Adalimumab Monoclonal Antibody Biosimilar Basic Information
9.10.2 Coherus Adalimumab Monoclonal Antibody Biosimilar Product Overview
9.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Product Market Performance
9.10.4 Coherus Business Overview
9.10.5 Coherus Recent Developments
10 Adalimumab Monoclonal Antibody Biosimilar Market Forecast by Region
10.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Forecast
10.2 Global Adalimumab Monoclonal Antibody Biosimilar Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size Forecast by Country
10.2.3 Asia Pacific Adalimumab Monoclonal Antibody Biosimilar Market Size Forecast by Region
10.2.4 South America Adalimumab Monoclonal Antibody Biosimilar Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Adalimumab Monoclonal Antibody Biosimilar by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Adalimumab Monoclonal Antibody Biosimilar by Type (2025-2030)
11.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Adalimumab Monoclonal Antibody Biosimilar by Type (2025-2030)
11.2 Global Adalimumab Monoclonal Antibody Biosimilar Market Forecast by Application (2025-2030)
11.2.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales (Kilotons) Forecast by Application
11.2.2 Global Adalimumab Monoclonal Antibody Biosimilar Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings